PARP inhibition: PARP1 and beyond

Nature Reviews Cancer

Volumn 10, Issue 4, 2010, Pages 293-301

  Rouleau, Michèle ^a   Patel, Anand ^b   Hendzel, Michael J ^c   Kaufmann, Scott H ^b   Poirier, Guy G ^a  

^a UNIVERSITÉ LAVAL   (Canada)

^b MAYO GRADUATE SCHOOL   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 3 AMINOBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BSI 201; CARBOPLATIN; CEP 8983; CEP 9722; CYCLOPHOSPHAMIDE; DIMETHYLHYDRAZINE; GEMCITABINE; GYRASE INHIBITOR; MK 4872; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; XAV 939;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; CLINICAL TRIAL; DNA DAMAGE; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME STRUCTURE; GLIOBLASTOMA; HUMAN; IONIZING RADIATION; LEUKEMIA; NONHUMAN; NOTE; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN FUNCTION; SOLID TUMOR; UTERUS CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; DACARBAZINE; DEOXYCYTIDINE; DNA DAMAGE; DNA, NEOPLASM; HUMANS; KINETICS; MICE; NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; SUBSTRATE SPECIFICITY;

EID: 77950023283     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2812     Document Type: Note

References (141)

1. Chambon, P., Weill, J. D. & Mandel, P. Nicotinamide mononucleotide activation of new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem. Biophys. Res. Commun. 11, 39-43 (1963).
2. Doly, J. & Petek, F. Etude de la structure d'un composé "poly(ADP-ribose)" synthétisé par des extraits nucléaires de foie de poulet. C. R. Hebd. Seances Acad. Sci. Ser. D Sci. Nat. 263, 1341-1344 (1966).
3. Chambon, P., Weill, J. D., Doly, J., Strosser, M. T. & Mandel, P. On the formation of a novel adelylic compound by enzymatic extracts of liver nuclei. Biochem. Biophys. Res. Commun. 25, 638-643 (1966).
4. Nishizuka, Y., Ueda, K., Nakazawa, K. & Hayaishi, O. Studies on the polymer of adenosine diphosphate ribose. I. Enzymic formation from nicotinamide adenine dinuclotide in mammalian nuclei. J. Biol. Chem. 242, 3164-3171 (1967).
5. Sugimura, T., Fujimura, S., Hasegawa, S. & Kawamura, Y. Polymerization of the adenosine 5′-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim. Biophys. Acta 138, 438-441 (1967).
6. Yamada, M., Miwa, M. & Sugimura, T. Studies on poly (adenosine diphosphate-ribose): X. Properties of a partially purified poly (adenosine diphosphate-ribose) polymerase. Arch. Biochem. Biophys. 146, 579-586 (1971).
7. Okayama, H., Edson, C. M., Fukushima, M., Ueda, K. & Hayaishi, O. Purification and properties of poly(adenosine diphosphate ribose) synthetase. J. Biol. Chem. 252, 7000-7005 (1977).
8. Juarez-Salinas, H., Sims, J. L. & Jacobson, M. K. Poly(ADP-ribose) levels in carcinogen-treated cells. Nature 282, 740-741 (1979).
9. Benjamin, R. C. & Gill, D. M. ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage in DNA. J. Biol. Chem. 255, 10493-10501 (1980).
10. n participates in DNA excision repair. Nature 283, 593-596 (1980).
11. Shall, S. & de Murcia, G. Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model? Mutat. Res. 460, 1-15 (2000).
12. Amé, J. C. et al. PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J. Biol. Chem. 274, 17860-17868 (1999).
13. Berger, S. J., Sudar, D. C. & Berger, N. A. Metabolic consequences of DNA damage: DNA damage induces alterations in glucose metabolism by activation of poly (ADP-ribose) polymerase. Biochem. Biophys. Res. Commun. 134, 227-232 (1986).
14. Carson, D. A., Carrera, C. J., Wasson, D. B. & Yamanaka, H. Programmed cell death and adenine deoxynucleotide metabolism in human lymphocytes. Adv. Enzyme Regul. 27, 395-404 (1988).
15. David, K. K., Andrabi, S. A., Dawson, T. M. & Dawson, V. L. Parthanatos, a messenger of death. Front. Biosci. 14, 1116-1128 (2009).
16. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005).
17. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
18. Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
19. Gradwohl, G. et al. The second zinc-finger domain of poly(ADP-ribose) polymerase determines specificity for single-stranded breaks in DNA. Proc. Natl Acad. Sci. USA 87, 2990-2994 (1990).
20. Hassa, P. O. & Hottiger, M. O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci. 13, 3046-3082 (2008).
21. Langelier, M. F., Servent, K. M., Rogers, E. E. & Pascal, J. M. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation. J. Biol. Chem. 283, 4105-4114 (2008).
22. Tao, Z., Gao, P., Hoffman, D. W. & Liu, H. W. Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif. Biochemistry 47, 5804-5813 (2008).
23. Altmeyer, M., Messner, S., Hassa, P. O., Fey, M. & Hottiger, M. O. Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites. Nucleic Acids Res. 37, 3723-3738 (2009).
24. Tao, Z., Gao, P. & Liu, H. W. Identification of the ADP-ribosylation sites in the PARP-1 automodification domain: analysis and implications. J. Am. Chem. Soc. 131, 14258-14260 (2009).
25. Kameshita, I., Matsuda, Z., Taniguchi, T. & Shizuta, Y. Poly (ADP-ribose) synthetase. Separation and identification of three proteolytic fragments as the substrate-binding domain, the DNA-binding domain, and the automodification domain. J. Biol. Chem. 259, 4770-4776 (1984).
26. Haince, J. F. et al. PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites. J. Biol. Chem. 283, 1197-1208 (2008).
27. D'Amours, D., Desnoyers, S., D'Silva, I. & Poirier, G. G. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342, 249-268 (1999).
28. Gagné, J. P. et al. Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes. Nucleic Acids Res. 36, 6959-6976 (2008).
29. Timinszky, G. et al. A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation. Nature Struct. Mol. Biol. 16, 923-929 (2009).
30. Kraus, W. L. New functions for an ancient domain. Nature Struct. Mol. Biol. 16, 904-907 (2009).
31. Ahel, D. et al. Poly(ADP-ribose)-dependent regulation of DNA repair by the chromatin remodeling enzyme ALC1. Science 325, 1240-1243 (2009).
32. Gottschalk, A. J. et al. Poly(ADP-ribosyl)ation directs recruitment and activation of an ATP-dependent chromatin remodeler. Proc. Natl Acad. Sci. USA 106, 13770-13774 (2009).
33. Masson, M. et al. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol. Cell Biol. 18, 3563-3571 (1998).
34. El-Khamisy, S. F., Masutani, M., Suzuki, H. & Caldecott, K. W. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 31, 5526-5533 (2003).
35. Ogata, N., Ueda, K., Kagamiyama, H. & Hayaishi, O. ADP-ribosylation of histone H1. Identification of glutamic acid residues 2, 14, and the COOH-terminal lysine residue as modification sites. J. Biol. Chem. 255, 7616-7620 (1980).
36. Poirier, G. G., de Murcia, G., Jongstra-Bilen, J., Niedergang, C. & Mandel, P. Poly(ADP-ribosyl)ation of polynucleosomes causes relaxation of chromatin structure. Proc. Natl Acad. Sci. USA 79, 3423-3427 (1982).
37. Tulin, A. & Spradling, A. Chromatin loosening by poly(ADP)-ribose polymerase (PARP) at Drosophila puff loci. Science 299, 560-562 (2003).
38. Satoh, M. S. & Lindahl, T. Role of poly(ADP-ribose) formation in DNA repair. Nature 356, 356-358 (1992).
39. Zahradka, P. & Ebisuzaki, K. A shuttle mechanism for DNA-protein interactions. The regulation of poly(ADP-ribose) polymerase. Eur. J. Biochem. 127, 579-585 (1982).
40. Meyer-Ficca, M. L., Meyer, R. G., Coyle, D. L., Jacobson, E. L. & Jacobson, M. K. Human poly(ADP-ribose) glycohydrolase is expressed in alternative splice variants yielding isoforms that localize to different cell compartments. Exp. Cell Res. 297, 521-532 (2004).
41. Oka, S., Kato, J. & Moss, J. Identification and characterization of a mammalian 39-kDa poly(ADP-ribose) glycohydrolase. J. Biol. Chem. 281, 705-713 (2006).
42. Oka, J., Ueda, K., Hayaishi, O., Komura, H. & Nakanishi, K. ADP-ribosyl protein lyase. Purification, properties, and identification of the product. J. Biol. Chem. 259, 986-995 (1984).
43. Okayama, H., Honda, M. & Hayaishi, O. Novel enzyme from rat liver that cleaves an ADP-ribosyl histone linkage. Proc. Natl Acad. Sci. USA 75, 2254-2257 (1978).
44. Hardie, D. G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nature Rev. Mol. Cell Biol. 8, 774-785 (2007).
45. Huang, Q., Wu, Y. T., Tan, H. L., Ong, C. N. & Shen, H. M. A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress. Cell Death Differ. 16, 264-277 (2009).
46. Haince, J. F. et al. Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents. J. Biol. Chem. 282, 16441-16453 (2007).
47. Yang, Y. G., Cortes, U., Patnaik, S., Jasin, M. & Wang, Z. Q. Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks. Oncogene 23, 3872-3882 (2004).
48. Sugimura, K., Takebayashi, S., Taguchi, H., Takeda, S. & Okumura, K. PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA. J. Cell Biol. 183, 1203-1212 (2008).
49. Bryant, H. E. et al. PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J. 28, 2601-2615 (2009).
50. Audebert, M., Salles, B. & Calsou, P. Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining. J. Biol. Chem. 279, 55117-55126 (2004).
51. Veuger, S. J., Curtin, N. J., Smith, G. C. & Durkacz, B. W. Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair. Oncogene 23, 7322-7329 (2004).
52. Wang, M. et al. PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways. Nucleic Acids Res. 34, 6170-6182 (2006).
53. Caiafa, P., Guastafierro, T. & Zampieri, M. Epigenetics: poly(ADP-ribosyl)ation of PARP-1 regulates genomic methylation patterns. FASEB J. 23, 672-678 (2009).
54. Kraus, W. L. Transcriptional control by PARP-1: chromatin modulation, enhancer-binding, coregulation, and insulation. Curr. Opin. Cell Biol. 20, 294-302 (2008).
55. Krishnakumar, R. et al. Reciprocal binding of PARP-1 and histone H1 at promoters specifies transcriptional outcomes. Science 319, 819-821 (2008).
56. Simbulan-Rosenthal, C. M. et al. Misregulation of gene expression in primary fibroblasts lacking poly(ADP-ribose) polymerase. Proc. Natl Acad. Sci. USA 97, 11274-11279 (2000).
57. Frizzell, K. M. et al. Global analysis of transcriptional regulation by poly(ADP-ribose) polymerase-1 and poly(ADP-ribose) glycohydrolase in MCF-7 human breast cancer cells. J. Biol. Chem. 284, 33926-33938 (2009).
58. Amé, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. Bioessays 26, 882-893 (2004).
59. Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57-69 (2008).
60. Karlberg, T., Hammarstrom, M., Schutz, P., Svensson, L. & Schuler, H. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry 49, 1056-1058 (2010).
61. Lehtio, L. et al. Zinc binding catalytic domain of human tankyrase 1. J. Mol. Biol. 379, 136-145 (2008).
62. Lehtio, L. et al. Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J. Med. Chem. 52, 3108-3111 (2009).
63. Ménissier de Murcia, J. et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 22, 2255-2263 (2003).
64. Chiang, Y. J. et al. Tankyrase 1 and tankyrase 2 are essential but redundant for mouse embryonic development. PLoS ONE 3, e2639 (2008).
65. Yelamos, J., Schreiber, V. & Dantzer, F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol. Med. 14, 169-178 (2008).
66. Shieh, W. M. et al. Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J. Biol. Chem. 273, 30069-30072 (1998).
67. Sallmann, F. R., Vodenicharov, M. D., Wang, Z. Q. & Poirier, G. G. Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks. J. Biol. Chem. 275, 15504-15511 (2000).
68. Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q. & Thompson, C. B. Alkylating DNA damage stimulates a regulated form of necrotic cell death. Genes Dev. 18, 1272-1282 (2004).
69. Liu, Y. et al. Vault poly(ADP-ribose) polymerase is associated with mammalian telomerase and is dispensable for telomerase function and vault structure in vivo. Mol. Cell. Biol. 24, 5314-5323 (2004).
70. Raval-Fernandes, S., Kickhoefer, V. A., Kitchen, C. & Rome, L. H. Increased susceptibility of vault poly(ADP-ribose) polymerase-deficient mice to carcinogen-induced tumorigenesis. Cancer Res. 65, 8846-8852 (2005).
71. Hsiao, S. J. & Smith, S. Tankyrase function at telomeres, spindle poles, and beyond. Biochimie 90, 83-92 (2008).
72. Sbodio, J. I. & Chi, N. W. Identification of a tankyrase-binding motif shared by IRAP, TAB182, and human TRF1 but not mouse TRF1. NuMA contains this RXXPDG motif and is a novel tankyrase partner. J. Biol. Chem. 277, 31887-31892 (2002).
73. Canudas, S. et al. Protein requirements for sister telomere association in human cells. EMBO J. 26, 4867-4878 (2007).
74. Hsiao, S. J. & Smith, S. Sister telomeres rendered dysfunctional by persistent cohesion are fused by NHEJ. J. Cell Biol. 184, 515-526 (2009).
75. Huang, S. M. et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature 461, 614-620 (2009).
76. Nobori, T., Yamanaka, H. & Carson, D. A. Poly(ADP-ribose) polymerase inhibits DNA synthesis initiation in the absence of NAD. Biochem. Biophys. Res. Commun. 163, 1113-1118 (1989).
77. Zaremba, T. & Curtin, N. J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem. 7, 515-523 (2007).
78. Satoh, M. S., Poirier, G. G. & Lindahl, T. Dual function for poly(ADP-ribose) synthesis in response to DNA strand breakage. Biochemistry 33, 7099-7106 (1994).
79. Farzaneh, F., Zalin, R., Brill, D. & Shall, S. DNA strand breaks and ADP-ribosyl transferase activation during cell differentiation. Nature 300, 362-366 (1982).
80. Johnstone, A. P. & Williams, G. T. Role of DNA breaks and ADP-ribosyl transferase activity in eukaryotic differentiation demonstrated in human lymphocytes. Nature 300, 368-370 (1982).
81. Saleh-Gohari, N. et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol. Cell Biol. 25, 7158-7169 (2005).
82. Anders, C. & Carey, L. A. Understanding and treating triple-negative breast cancer. Oncology 22, 1233-1239 (2008).
83. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev. Cancer 4, 814-819 (2004).
84. McCabe, N. et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66, 8109-8115 (2006).
85. Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315-322 (2009).
86. Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res. 68, 10021-10023 (2008).
87. Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116-1120 (2008).
88. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
89. Ratnam, K. & Low, J. A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res. 13, 1383-1388 (2007).
90. Plummer, R. et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923 (2008).
91. O'Shaughnessy, J. et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. J. Clin. Oncol. 27, 3 (2009).
92. Ossovskaya, V. et al. BSI-201 enhances the activity of multiple classes of cytotoxic agents and irradiation in triple negative breast cancer. Abstract 5552. Proc. Annu. Meet. Am. Assoc. Cancer Res. (2009).
93. Pacher, P. & Szabo, C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc. Drug Rev. 25, 235-260 (2007).
94. Goldberg, S., Visochek, L., Giladi, E., Gozes, I. & Cohen-Armon, M. PolyADP-ribosylation is required for long-term memory formation in mammals. J. Neurochem. 111, 72-79 (2009).
95. Morrison, C. et al. Genetic interaction between PARP and DNA-PK in V(D)J. recombination and tumorigenesis. Nature Genet. 17, 479-482 (1997).
96. Tong, W. M. et al. Synergistic role of Ku80 and poly(ADP-ribose) polymerase in suppressing chromosomal aberrations and liver cancer formation. Cancer Res. 62, 6990-6996 (2002).
97. -/- mice. Am. J. Pathol. 162, 343-352 (2003).
98. Lilyestrom, W., van der Woerd, M. J., Clark, N. & Luger, K. Structural and biophysical studies of human PARP-1 in complex with damaged DNA. J. Mol. Biol. 395, 983-994 (2010).
99. Formentini, L. et al. Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J. Biol. Chem. 284, 17668-17676 (2009).
100. Loseva, O. et al. Poly(ADP-ribose) polymerase-3 (PARP-3) is a mono-ADP ribosylase that activates PARP-1 in absence of DNA. J. Biol. Chem. 11 Jan 2010 (doi: 10.1074/jbc.M109.077834).
101. McCabe, N. et al. Targeting tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene 28, 1465-1470 (2009).
102. Turner, N. C. et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J. 27, 1368-1377 (2008).
103. Mendeleyev, J., Kirsten, E., Hakam, A., Buki, K. G. & Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol. 50, 705-714 (1995).
104. Moore, J. et al. Treatment of cancer. US Patent Application Publication US2008/0103104 A1 (2008).
105. + ADP ribosyl transferase in rats. Toxicol. Pathol. 14, 483-488 (1986).
106. + ADP ribosyl transferase in rats. Carcinogenesis 5, 901-906 (1984).
107. Andrabi, S. A. et al. Poly(ADP-ribose) (PAR) polymer is a death signal. Proc. Natl Acad. Sci. USA 103, 18308-18313 (2006).
108. McLennan, A. G. The Nudix hydrolase superfamily. Cell. Mol. Life Sci. 63, 123-143 (2006).
109. Huang, Q. & Shen, H. M. To die or to live: the dual role of poly(ADP-ribose) polymerase-1 in autophagy and necrosis under oxidative stress and DNA damage. Autophagy 5, 273-276 (2009).
110. Munoz-Gamez, J. A. et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 5, 61-74 (2009).
111. Otto, H. et al. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC Genomics 6, 139 (2005).
112. Alvarez-Gonzalez, R. & Jacobson, M. K. Characterization of polymers of adenosine diphosphate ribose generated in vitro and in vivo. Biochemistry 26, 3218-3224 (1987).
113. Rippmann, J. F., Damm, K. & Schnapp, A. Functional characterization of the poly(ADP-ribose) polymerase activity of tankyrase 1, a potential regulator of telomere length. J. Mol. Biol. 323, 217-224 (2002).
114. Sbodio, J. I., Lodish, H. F. & Chi, N. W. Tankyrase-2 oligomerizes with tankyrase-1 and binds to both TRF1 (telomere-repeat-binding factor 1) and IRAP (insulin-responsive aminopeptidase). Biochem. J. 361, 451-459 (2002).
115. Augustin, A. et al. PARP-3 localizes preferentially to the daughter centriole and interferes with the G1/S cell cycle progression. J. Cell Sci. 11 6, 1551-1562 (2003).
116. Bauer, P. I., Buki, K. G., Hakam, A. & Kun, E. Macromolecular association of ADP-ribosyltransferase and its correlation with enzymic activity. Biochem. J. 270, 17-26 (1990).
117. Mendoza-Alvarez, H. & Alvarez-Gonzalez, R. Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J. Biol. Chem. 268, 22575-22580 (1993).
118. de Murcia, J. M. et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA 94, 7303-7307 (1997).
119. Masutani, M. et al. Function of poly(ADP-ribose) polymerase in response to DNA damage: gene-disruption study in mice. Mol. Cell Biochem. 193, 149-152 (1999).
120. Wang, Z. Q. et al. Mice lacking ADPRT and poly(ADP-ribosyl)ation develop normally but are susceptible to skin disease. Genes Dev. 9, 509-520 (1995).
121. + double-positive thymocytes. EMBO J. 25, 4350-4360 (2006).
122. Yeh, T. Y. et al. Hypermetabolism, hyperphagia, and reduced adiposity in tankyrase-deficient mice. Diabetes 58, 2476-2485 (2009).
123. Chiang, Y. J. et al. Generation and characterization of telomere length maintenance in tankyrase 2-deficient mice. Mol. Cell. Biol. 26, 2037-2043 (2006).
124. Hsiao, S. J., Poitras, M. F., Cook, B. D., Liu, Y. & Smith, S. Tankyrase 2 poly(ADP-ribose) polymerase domain-deleted mice exhibit growth defects but have normal telomere length and capping. Mol. Cell. Biol. 26, 2044-2054 (2006).
125. Albert, J. M. et al. Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin. Cancer Res. 13, 3033-3042 (2007).
126. Clarke, M. J. et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol. Cancer Ther. 8, 407-414 (2009).
127. Donawho, C. K. et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin. Cancer Res. 13, 2728-2737 (2007).
128. Horton, T. M. et al. Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol. Cancer Ther. 8, 2232-2242 (2009).
129. Liu, S. K. et al. A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia. Radiother Oncol. 88, 258-268 (2008).
130. Liu, X. et al. Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol. Cancer Res. 6, 1621-1629 (2008).
131. Penning, T. D. et al. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R.)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J. Med. Chem. 52, 514-523 (2009).
132. Daniel, R. A. et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res. 15, 1241-1249 (2009).
133. Thomas, H. D. et al. Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol. Cancer Ther. 6, 945-956 (2007).
134. Dungey, F. A., Caldecott, K. W. & Chalmers, A. J. Enhanced radiosensitization of human glioma cells by combining inhibition of poly(ADP-ribose) polymerase with inhibition of heat shock protein 90. Mol. Cancer Ther. 8, 2243-2254 (2009).
135. Dungey, F. A., Loser, D. A. & Chalmers, A. J. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: mechanisms and therapeutic potential. Int. J. Radiat. Oncol. Biol. Phys. 72, 1188-1197 (2008).
136. Evers, B. et al. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin. Cancer Res. 14, 3916-3925 (2008).
137. Hay, T. et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res. 69, 3850-3855 (2009).
138. Menear, K. A. et al. 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)- 4-fluorobenzyl]-2H-phth alazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J. Med. Chem. 51, 6581-6591 (2008).
139. Rottenberg, S. et al. High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc. Natl Acad. Sci. USA 105, 17079-17084 (2008).
140. Miknyoczki, S. et al. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther. 6, 2290-2302 (2007).
141. Jones, P. et al. Discovery of 2-{4-[(3S)-Piperidin-3-yl] phenyl}-2H-indazole-7-.carboxamide (MK-4827): a novel oral poly(ADP-ribose) polymerase (PARP) inhibitor+ efficacious in BRCA-1 and-2 mutant tumors. J. Med. Chem. 52, 7170-7185 (2009).